Baillie Gifford & Co. raised its position in STAAR Surgical Company (NASDAQ:STAA) by 36.2% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 666,612 shares of the medical instruments supplier’s stock after buying an additional 177,072 shares during the period. Baillie Gifford & Co. owned about 1.63% of STAAR Surgical worth $7,199,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently made changes to their positions in STAA. Teachers Advisors LLC boosted its position in STAAR Surgical by 3.7% in the 4th quarter. Teachers Advisors LLC now owns 71,882 shares of the medical instruments supplier’s stock valued at $780,000 after buying an additional 2,549 shares during the last quarter. Strs Ohio bought a new position in STAAR Surgical in the 1st quarter valued at $251,000. Wells Fargo & Company MN boosted its position in STAAR Surgical by 30.6% in the 1st quarter. Wells Fargo & Company MN now owns 67,262 shares of the medical instruments supplier’s stock valued at $659,000 after buying an additional 15,769 shares during the last quarter. Bank of New York Mellon Corp boosted its position in STAAR Surgical by 0.9% in the 1st quarter. Bank of New York Mellon Corp now owns 160,186 shares of the medical instruments supplier’s stock valued at $1,569,000 after buying an additional 1,392 shares during the last quarter. Finally, Trexquant Investment LP boosted its position in STAAR Surgical by 30.8% in the 1st quarter. Trexquant Investment LP now owns 22,105 shares of the medical instruments supplier’s stock valued at $217,000 after buying an additional 5,205 shares during the last quarter. Hedge funds and other institutional investors own 76.54% of the company’s stock.

A number of research analysts have commented on STAA shares. Zacks Investment Research upgraded STAAR Surgical from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Canaccord Genuity reiterated a “hold” rating on shares of STAAR Surgical in a research report on Tuesday, July 11th. BidaskClub upgraded STAAR Surgical from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. TheStreet upgraded STAAR Surgical from a “d+” rating to a “c” rating in a research report on Tuesday, August 15th. Finally, Benchmark Co. increased their price objective on STAAR Surgical from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Monday, August 14th. Three research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $12.00.

ILLEGAL ACTIVITY WARNING: “Baillie Gifford & Co. Purchases 177,072 Shares of STAAR Surgical Company (STAA)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/12/baillie-gifford-co-purchases-177072-shares-of-staar-surgical-company-staa.html.

STAAR Surgical Company (NASDAQ STAA) opened at 11.85 on Tuesday. The stock has a 50 day moving average price of $11.29 and a 200-day moving average price of $10.22. STAAR Surgical Company has a 1-year low of $7.45 and a 1-year high of $12.35. The firm’s market cap is $487.13 million.

STAAR Surgical (NASDAQ:STAA) last issued its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.04. STAAR Surgical had a negative net margin of 6.06% and a negative return on equity of 8.69%. The company had revenue of $21.90 million for the quarter, compared to analysts’ expectations of $22.15 million. During the same quarter in the previous year, the firm posted ($0.02) earnings per share. STAAR Surgical’s revenue for the quarter was up 4.8% on a year-over-year basis. Equities research analysts forecast that STAAR Surgical Company will post ($0.11) EPS for the current year.

STAAR Surgical Company Profile

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.

Institutional Ownership by Quarter for STAAR Surgical (NASDAQ:STAA)

Receive News & Stock Ratings for STAAR Surgical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical Company and related stocks with our FREE daily email newsletter.